The first phase of a clinical trial showed that vaccination of newly diagnosed glioblastomas with a personalized neoantigen vaccine (NeoVax) induced neoantigen-specific circulating CD4+ and CD8+ T-cell responses and neoantigen specific intratumoral T-cell infiltration (NCT02287428) [48,49]. The gene discussed is CD8A; the disease is glioblastoma.